Solid Tumor, Adult Clinical Trials in San Francisco, California

11 studies are recruiting for solid tumor, adult in San Francisco, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

   First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   44 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06625775 on ClinicalTrials.gov

2. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   48 in total

   Run by

   Pierre Fabre Medicament

   See if you can join NCT04913285 on ClinicalTrials.gov

3. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Medical Center at Mount Zion, San Francisco, California

   Locations

   16 in total

   Run by

   Tyra Biosciences, Inc

   See if you can join NCT06915753 on ClinicalTrials.gov

4. BBO-11818 in Adult Subjects With KRAS Mutant Cancer

   A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   17 in total

   Run by

   TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

   See if you can join NCT06917079 on ClinicalTrials.gov

5. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

   The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF, San Francisco, California

   Locations

   19 in total

   Run by

   NiKang Therapeutics, Inc.

   See if you can join NCT06586957 on ClinicalTrials.gov

6. A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

   This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment opti…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   23 in total

   Run by

   Nested Therapeutics, Inc

   See if you can join NCT06326411 on ClinicalTrials.gov

7. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

   This is an open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, and biological activity of VT3989 administered, alone or in combination, once daily in patients with mesothelioma and/or metastatic solid tumors that are resistant to standard therapy or for which n…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   12 in total

   Run by

   Vivace Therapeutics, Inc

   See if you can join NCT04665206 on ClinicalTrials.gov

8. A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

   The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase 2 (Cohort Expansion). Multiple dose levels in participants w…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California

   Locations

   26 in total

   Run by

   Frontier Medicines Corporation

   See if you can join NCT06244771 on ClinicalTrials.gov

9. 64Cu-GRIP B in Patients With Advanced Malignancies

   This phase I/II clinical trial evaluates if using a radiotracer targeting granzyme B, 64-copper granzyme targeting restricted interaction peptide specific to family member B (64 Cu-GRIP B) with positron emission tomography (PET) imaging can be safe and useful for detecting granzyme B (GrB) in patie…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   Rahul Aggarwal

   See if you can join NCT05888532 on ClinicalTrials.gov

10. A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

    The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively w…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Helen Diller Family Comprehensive Cancer Center - UCSF, San Francisco, California

    Locations

    41 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06265727 on ClinicalTrials.gov

11. A Beta-only IL-2 ImmunoTherapY Study

    This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California

    Locations

    27 in total

    Run by

    Medicenna Therapeutics, Inc.

    See if you can join NCT05086692 on ClinicalTrials.gov